COMPANY

Linnaeus Therapeutics

HQ: Haddonfield, NJ source · linnaeustx.com ↗

Keywords: From press sources:skin melanoma

Location: Haddonfield, NJ · source · Apr 2, 2026

Profile checked Oct 10, 2026

Funding and NIH signals

SEC Form D raise Raised $4.99M (Form D filed Feb 27, 2026; amended Apr 2, 2026). SEC Form D 0001752026-26-000004 (Feb 27, 2026)
Evidence (1 event)
- Feb 27, 2026 · SEC Form D 0001752026-26-000004
  Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D; Filing date: 2026-02-27; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4475000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-03-13; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4792000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-03-31; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4892000; Federal exemptions: 06b || Name of Issuer: Linnaeus Therapeutics, Inc.; CIK: 1752026; Address: Haddonfield, NJ; Submission type: D/A; Filing date: 2026-04-02; Industry Group: Biotechnology; Date of First Sale: 2026-02-17; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 10000000; Total Amount Sold: 4992000; Federal exemptions: 06b
NIH award NIH awarded $1M (SBIR Phase II 5R44CA297994-02, continuation, notice May 19, 2026). NIH RePORTER 5R44CA297994-02 (May 19, 2026)
Evidence (1 event)
- May 19, 2026 · NIH RePORTER 5R44CA297994-02
  Organization: LINNAEUS THERAPEUTICS INC; City/State: HADDONFIELD, NJ; Project number: 5R44CA297994-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 999960; Administering IC: National Cancer Institute; Project title: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals